Skip to main content
NCBI home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1980 Aug;10(2):135–143. doi: 10.1111/j.1365-2125.1980.tb01730.x

Comparative pharmacokinetics and pharmacodynamics of cardiac glycosides.

A W Kelman, D J Sumner, M Lonsdale, J R Lawrence, B Whiting
PMCID: PMC1430039  PMID: 7426275

Abstract

1 The pharmacokinetics and pharmacodynamics of ouabain, digoxinn and beta-methyl digoxin (medigoxin) have been investigated in a crossover study in four normal healthy volunteers. 2 Pharmacokinetics were studied using [3H]-labelled glycosides and the shortening of the left ventricular ejection time (LVET) was used as a measure of the effect of the drugs. A graded exercise protocol was used to correct for the effects of heart rate on LVET. 3 In three of the four subjects, both digoxin and beta-methyl digoxin produced a shortening in the LVET, but no such change could be detected with ouabain in any of the four subjects. 4 There was a good linear correlation between the shortening of the LVET and the amounts of digoxin or beta-methyl digoxin present in the body tissues. 5 One subject who showed no drug-related LVET shortening had greatly enhanced clearances of all three drugs studied.

Full text

PDF
135

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Boerner D., Olcay A., Schaumann W., Weiss W. Absorption of beta-methyl-digoxin determined after a single dose and under steady state conditions. Eur J Clin Pharmacol. 1976 Feb 6;9(4):307–314. doi: 10.1007/BF00561665. [DOI] [PubMed] [Google Scholar]
  2. COX E., ROXBURGH G., WRIGHT S. E. The metabolism of ouabain in the rat. J Pharm Pharmacol. 1959 Sep;11:535–539. doi: 10.1111/j.2042-7158.1959.tb12592.x. [DOI] [PubMed] [Google Scholar]
  3. Clark D. R., Kalman S. M. Dihydrodigoxin: a common metabolite of digoxin in man. Drug Metab Dispos. 1974 Mar-Apr;2(2):148–150. [PubMed] [Google Scholar]
  4. Das G. P., Talmers R. N., Weissler A. M. Comparative pharmacodynamics of betamethyl digoxin and digoxin in man. Clin Pharmacol Ther. 1977 Sep;22(3):280–285. doi: 10.1002/cpt1977223280. [DOI] [PubMed] [Google Scholar]
  5. Dobbs S. M., Kenyon W. I., Dobbs R. J. Maintenance digoxin after an episode of heart failure: placebo-controlled trial in outpatients. Br Med J. 1977 Mar 19;1(6063):749–752. doi: 10.1136/bmj.1.6063.749. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Doherty J. E. Digitalis glycosides. Pharmacokinetics and their clinical implications. Ann Intern Med. 1973 Aug;79(2):229–238. doi: 10.7326/0003-4819-79-2-229. [DOI] [PubMed] [Google Scholar]
  7. Garrett E. R., Hinderling P. H. Pharmacokinetics of beta-methyldigoxin in healthy humans IV: comparisons of radioimmunoassays, total radioactivity, and specific assays of beta-methyldigoxin and digoxin in plasma. J Pharm Sci. 1977 Jun;66(6):806–810. doi: 10.1002/jps.2600660616. [DOI] [PubMed] [Google Scholar]
  8. Harrison L. I., Gibaldi M. Physiologically based pharmacokinetic model for digoxin disposition in dogs and its preliminary application to humans. J Pharm Sci. 1977 Dec;66(12):1679–1683. doi: 10.1002/jps.2600661206. [DOI] [PubMed] [Google Scholar]
  9. Hinderling P. H., Garrett E. R. Pharmacokinetics of beta-methyldigoxin in healthy humans III: Pharmacodynamic correlations. J Pharm Sci. 1977 Mar;66(3):326–329. doi: 10.1002/jps.2600660305. [DOI] [PubMed] [Google Scholar]
  10. Kelman A. W., Sumner D. J., Lawrence J. R., Whiting B. Measurement of systolic time intervals. Br J Clin Pharmacol. 1978 Dec;6(6):549–550. doi: 10.1111/j.1365-2125.1978.tb00886.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Koup J. R., Greenblatt D. J., Jusko W. J., Smith T. W., Koch-Weser J. Pharmacokinetics of digoxin in normal subjects after intravenous bolus and infusion doses. J Pharmacokinet Biopharm. 1975 Jun;3(3):181–192. doi: 10.1007/BF01067907. [DOI] [PubMed] [Google Scholar]
  12. Kramer P., Scheler F. Renale Eliminationskinetik verschiedener Herzglykoside. Dtsch Med Wochenschr. 1972 Oct 6;97(40):1485–1490. doi: 10.1055/s-0028-1107587. [DOI] [PubMed] [Google Scholar]
  13. Kramer W. G., Kolibash A. J., Lewis R. P., Bathala M. S., Visconti J. A., Reuning R. H. Pharmacokinetics of digoxin: relationship between response intensity and predicted compartmental drug levels in man. J Pharmacokinet Biopharm. 1979 Feb;7(1):47–61. doi: 10.1007/BF01059440. [DOI] [PubMed] [Google Scholar]
  14. Kramer W. G., Lewis R. P., Cobb T. C., Forester W. F., Jr, Visconti J. A., Wanke L. A., Boxenbaum H. G., Reuning R. H. Pharmacokinetics of digoxin: comparison of a two- and a three-compartment model in man. J Pharmacokinet Biopharm. 1974 Aug;2(4):299–312. doi: 10.1007/BF01061404. [DOI] [PubMed] [Google Scholar]
  15. Reuning R. H., Sams R. A., Notari R. E. Role of pharmacokinetics in drug dosage adjustment. I. Pharmacologic effect kinetics and apparent volume of distribution of digoxin. J Clin Pharmacol New Drugs. 1973 Apr;13(4):127–141. doi: 10.1002/j.1552-4604.1973.tb00074.x. [DOI] [PubMed] [Google Scholar]
  16. Rietbrock N., Abshagen U., Bergmann K., Rennekamp H. Disposition of beta-methyldigoxin in man. Eur J Clin Pharmacol. 1975 Dec 19;9(2-3):105–114. doi: 10.1007/BF00614005. [DOI] [PubMed] [Google Scholar]
  17. Rietbrock N., Guggenmos J., Kuhlmann J., Hess U. Bioavailability and pharmacokinetics of beta-methyldigoxin after multiple oral and intravenous doses. Eur J Clin Pharmacol. 1976 Mar 22;09(5-6):373–379. doi: 10.1007/BF00606551. [DOI] [PubMed] [Google Scholar]
  18. Selden R., Smith T. W. Ouabain pharmacokinetics in dog and man. Determination by radioimmunoassay. Circulation. 1972 Jun;45(6):1176–1182. doi: 10.1161/01.cir.45.6.1176. [DOI] [PubMed] [Google Scholar]
  19. Shapiro W., Narahara K., Taubert K. Relationship of plasma digitoxin and digoxin to cardiac response following intravenous digitalization in man. Circulation. 1970 Dec;42(6):1065–1072. doi: 10.1161/01.cir.42.6.1065. [DOI] [PubMed] [Google Scholar]
  20. Sheiner L. B., Stanski D. R., Vozeh S., Miller R. D., Ham J. Simultaneous modeling of pharmacokinetics and pharmacodynamics: application to d-tubocurarine. Clin Pharmacol Ther. 1979 Mar;25(3):358–371. doi: 10.1002/cpt1979253358. [DOI] [PubMed] [Google Scholar]
  21. Stoll R. G., Christensen M. S., Sakmar E., Wagner J. G. The specificity of the digoxin radioimmunoassay procedure. Res Commun Chem Pathol Pharmacol. 1972 Nov;4(3):503–510. [PubMed] [Google Scholar]
  22. Sumner D. J., Russell A. J. Digoxin pharmacokinetics: multicompartmental analysis and its clinical implications. Br J Clin Pharmacol. 1976 Apr;3(2):221–229. doi: 10.1111/j.1365-2125.1976.tb00596.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Wagner J. G. Linear pharmacokinetic equations allowing direct calculation of many needed pharmacokinetic parameters from the coefficients and exponents of polyexponential equations which have been fitted to the data. J Pharmacokinet Biopharm. 1976 Oct;4(5):443–467. doi: 10.1007/BF01062831. [DOI] [PubMed] [Google Scholar]
  24. Weissler A. M., Harris W. S., Schoenfeld C. D. Systolic time intervals in heart failure in man. Circulation. 1968 Feb;37(2):149–159. doi: 10.1161/01.cir.37.2.149. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES